Sumitomo Pharmaceuticals Co. Ltd.

9 articles about Sumitomo Pharmaceuticals Co. Ltd.

• European Commission Approves the Commercialisation of RYEQO® for the Symptomatic Treatment of Endometriosis

  11/2/2023

  Gedeon Richter Plc. together with Sumitomo Pharma America, Inc. and Sumitomo Pharma Switzerland, GmbH announce that the European Commission has granted approval of a Type II Variation application for RYEQO® for the symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.

• Exscientia Announces Sixth Molecule Created Through Generative AI Platform to Enter Clinical Stage

  5/15/2023

  Exscientia plc announced that Sumitomo Pharma Co., Ltd. plans to initiate a Phase 1 clinical study of DSP-2342 in the United States.

• 

  Weeks after Rejecting First Offer, Myovant Agrees to Acquisition by Sumitovant

  10/24/2022

  Myovant Sciences agreed to be acquired by Sumitovant Biopharma for $2.9 billion - three weeks after turning down a previous offer.
• 

  Jazz Adds Narcolepsy Pact with Sumitomo, Sees Clear Ahead to Vision 2025

  5/5/2022

  Jazz's Q1 included a key licensing deal with Werewolf Therapeutics and another announced Wednesday with Japan’s Sumitomo Pharma Co. for a narcolepsy treatment.

• Sumitomo Pharma Oncology Presents New Data from Investigational Pipeline of Novel Cancer Therapeutics at AACR Annual Meeting 2022

  4/8/2022

  Sumitomo Pharma Oncology, Inc. announced it will present new clinical and preclinical data on a range of investigational agents from the company's pipeline at the American Association for Cancer Research Annual Meeting, held April 8-13, 2022, in New Orleans, LA.

• Lefamulin Receives Approval in Taiwan for Treatment of Community-Acquired Pneumonia

  9/8/2021

  Nabriva Therapeutics plc, a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced that its partner, Sumitomo Pharmaceuticals Co., Ltd. has received approval to market oral and intravenous formulations of XENLETA® for the treatment of community-acquired pneumonia in adults in Taiwan.

• Sumitomo Pharmaceuticals Co. Ltd. to Act as Advisor to ProMetic BioSciences, Inc. for Japanese Market

  5/1/2009

• Dainippon Pharmaceutical, Sumitomo Pharmaceuticals Co. Ltd. And Ono Pharmaceutical Company, Ltd. To Enter Into Joint Development And Marketing Agreement For Limaprost Alfadex, Oral PGE1 Derivative

  12/7/2005

• Merger Mania Besets Japanese Pharmaceuticals

  2/23/2005